Zaher Hakim, MD
Interventional Cardiology · Detroit, MINPI 1306191853
Payments from drug & device makers
Across 428 payments — averaging $214.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Inari Medical, Inc.$66K
- Cardiovascular Systems Inc.$12K
- Penumbra, Inc.$2K
- Boston Scientific$2K
- Abbott$2K
- Stryker$1K
- plus $7K from 31 others
What the payments were for
- Consulting fees$3,8004%
- Speaking & faculty fees$65,25571%
- Travel & lodging$6,7537%
- Food & beverage$15,57817%
- Education$3090%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Inari Medical, Inc. | 81 | $66,203 |
| Cardiovascular Systems Inc. | 29 | $11,670 |
| Penumbra, Inc. | 12 | $2,176 |
| Boston Scientific | 72 | $1,870 |
| Abbott | 15 | $1,706 |
| Stryker | 27 | $1,417 |
| Edwards Lifesciences | 7 | $1,335 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 60 | $1,142 |
| Abiomed | 5 | $949 |
| Medtronic(2 entities) | 14 | $478 |
| Terumo Medical Corporation | 7 | $271 |
| Pfizer | 14 | $258 |
| Astellas Pharma US Inc | 3 | $216 |
| Amgen | 12 | $213 |
| Bard Peripheral Vascular, Inc. | 4 | $166 |
| Alnylam Pharmaceuticals Inc. | 6 | $152 |
| Shockwave Medical, Inc | 1 | $137 |
| Merck | 5 | $134 |
| Getinge USA Sales, LLC | 5 | $127 |
| ZOLL Circulation Inc | 1 | $125 |
| Johnson & Johnson | 5 | $121 |
| E.r. Squibb & Sons, L.L.C. | 7 | $119 |
| Boehringer Ingelheim | 6 | $115 |
| Novartis | 5 | $96 |
| AstraZeneca | 5 | $81 |
| Avinger Inc. | 4 | $72 |
| Kestra Medical Technology Services, Inc. | 3 | $65 |
| Heartflow, Inc. | 1 | $57 |
| Philips North America LLC | 3 | $53 |
| Teleflex LLC | 2 | $30 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $26 |
| Novo Nordisk | 1 | $24 |
| Bayer | 1 | $24 |
| Lexicon Pharmaceuticals, Inc. | 1 | $23 |
| CMP Pharma, Inc. | 1 | $16 |
| Cardiva Medical, Inc. | 1 | $14 |
| Cardinal Health 200 LLC | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FLOWTRIEVER CATHETER, S$67,304
- CT THROMBECTOMY SYSTEM KIT$63,221
- Diamondback Coronary$5,727
- Coronary Orbital Atherectomy System$4,301
- Indigo System$1,864
- Edwards SAPIEN 3 Transcatheter Heart Valve$1,117
- Peripheral Orbital Atherectomy System$1,041
- Impella$856
- PERCLOSE PROGLIDE$575
- AMPLATZER Occluders$485
- FlowTriever$381
- CLOTTRIEVER BOLD CATHETER$285
- Perclose ProStyle$275
- ClotTriever$246
- EMBLEM MRI S-ICD$232
- COBALT DR MRI SURESCAN$151
- Vascular Lithotripsy$137
- TherOx DS2 Console$125
- Catheter$125
- Downstream Cartridge$125
How this compares
$91,695 in reported general payments places this provider in the 75th percentile of 187 interventional cardiology providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 81 | $78,962 |
| EntrestoSacubitril/Valsartan | 46 | $53,323 |
| OzempicSemaglutide | 39 | $48,631 |
| XareltoRivaroxaban | 44 | $36,812 |
| EliquisApixaban | 37 | $34,940 |
| TrulicityDulaglutide | 15 | $14,524 |
| Repatha SureclickEvolocumab | 18 | $10,905 |
| Metoprolol Succinate | 126 | $1,523 |
| Ranolazine ErRanolazine | 17 | $1,424 |
| Carvedilol | 126 | $1,108 |
| ClopidogrelClopidogrel Bisulfate | 84 | $954 |
| Atorvastatin Calcium | 102 | $814 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 44 | $673 |
| Amiodarone Hcl | 18 | $522 |
| Chlorthalidone | 31 | $475 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $115 | $78,96281 claims |
| NovartisEntresto | $96 | $53,32346 claims |
| Novo NordiskOzempic | $24 | $48,63139 claims |
| Johnson & JohnsonXarelto | $121 | $36,81244 claims |
| PfizerEliquis | $258 | $34,94037 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 187 interventional cardiology providers in Michigan.
Other interventional cardiology in Detroit
- Amir KakiDetroit$2.3M
- Khaldoon AlaswadDetroit$1.1M
- Tamam MohamadDetroit$960K
- Mir BasirDetroit$771K
- M Chadi AlraiesDetroit$245K
- Brittany FullerDetroit$129K
- Delair GardiDetroit$63K
- William MerhiGrand Rapids$2M
- Shukri DavidSouthfield$1.6M
- Qaiser ShafiqSouthgate$1.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.